(Q28264580)

Radioimmunotherapy: designer molecules to potentiate effective therapy

21 January 2018

1 reference

Recent advances in radionuclide therapy

21 January 2018

1 reference

Clinical radioimmunotherapy

21 January 2018

1 reference

The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications

21 January 2018

1 reference

Tumor therapy with targeted atomic nanogenerators

21 January 2018

1 reference

Targeted therapy using alpha emitters

21 January 2018

1 reference

Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation

21 January 2018

1 reference

Auger electron emitters: insights gained from in vitro experiments

21 January 2018

1 reference

In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates

21 January 2018

1 reference

In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications

21 January 2018

1 reference

Copper-67 as a therapeutic nuclide for radioimmunotherapy

21 January 2018

1 reference

In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver.

21 January 2018

1 reference

High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment

21 January 2018

1 reference

Monoclonal antibody-based therapy strategies: providing options for the cancer patient

21 January 2018

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

The mechanisms of action of rituximab in the elimination of tumor cells

21 January 2018

1 reference

Monoclonal antibody-mediated tumor regression by induction of apoptosis.

21 January 2018

1 reference

Receptor blockade with monoclonal antibodies as anti-cancer therapy

21 January 2018

1 reference

Signaling antibodies in cancer therapy

21 January 2018

1 reference

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials

21 January 2018

1 reference

Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).

21 January 2018

1 reference

Monoclonal antibody therapy in lymphoid malignancies

21 January 2018

1 reference

Antibody-based treatment of acute myeloid leukaemia

21 January 2018

1 reference

Immunotherapy: past, present and future

21 January 2018

1 reference

The use of radioimmunoconjugates in stem cell transplantation.

21 January 2018

1 reference

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

21 January 2018

1 reference

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

21 January 2018

1 reference

Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

21 January 2018

1 reference

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

21 January 2018

1 reference

Bifunctional antibodies for radioimmunotherapy.

21 January 2018

1 reference

Antibodies with infinite affinity

21 January 2018

1 reference

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study

21 January 2018

1 reference

Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer

21 January 2018

1 reference

Comparison of Four Bifunctional Chelates for Radiolabeling Monoclonal Antibodies with Copper Radioisotopes: Biodistribution and Metabolism

21 January 2018

1 reference

The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody

21 January 2018

1 reference

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study

31 March 2020

1 reference

Radioimmunotherapy with alpha-emitting nuclides

31 March 2020

1 reference

Radionuclides for radioimmunotherapy: criteria for selection

31 March 2020

1 reference

212Bismuth Linked to an Antipancreatic Carcinoma Antibody: Model for Alpha-Particle-Emitter Radioimmunotherapy

31 March 2020

1 reference

Comparison of strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125

31 March 2020

1 reference

In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts

31 March 2020

1 reference

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

31 March 2020

1 reference

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

31 March 2020

1 reference

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

31 March 2020

1 reference

Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms

31 March 2020

1 reference

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

31 March 2020

1 reference

Metabolic characteristics within a chemical family

31 March 2020

1 reference

Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates

31 March 2020

1 reference